艰难梭菌疫苗及血清免疫球蛋白G对毒素A的抗体反应。
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.
作者信息
Aboudola Samer, Kotloff Karen L, Kyne Lorraine, Warny Michel, Kelly Eoin C, Sougioultzis Stavros, Giannasca Paul J, Monath Thomas P, Kelly Ciarán P
机构信息
Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
出版信息
Infect Immun. 2003 Mar;71(3):1608-10. doi: 10.1128/IAI.71.3.1608-1610.2003.
Abstract
There is a strong association between serum antibody responses to toxin A and protection against Clostridium difficile diarrhea. A parenteral C. difficile toxoid vaccine induced very-high-level responses to anti-toxin A immunoglobulin G (IgG) in the sera of healthy volunteers. After vaccination, the concentrations of anti-toxin A IgG in the sera of all 30 recipients exceeded the concentrations that were associated with protection in previous clinical studies. Furthermore, the median concentration of serum anti-toxin A IgG in the test group was 50-fold higher than the previous threshold. These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis.
摘要
血清对毒素A的抗体反应与预防艰难梭菌腹泻之间存在密切关联。一种肠道外注射的艰难梭菌类毒素疫苗在健康志愿者血清中诱导出了对抗毒素A免疫球蛋白G（IgG）的非常高水平的反应。接种疫苗后，所有30名接受者血清中的抗毒素A IgG浓度均超过了先前临床研究中与保护作用相关的浓度。此外，试验组血清抗毒素A IgG的中位数浓度比先前的阈值高50倍。这些发现支持了使用疫苗保护高危个体免受艰难梭菌相关性腹泻和结肠炎侵害的可行性。
相似文献
1
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.艰难梭菌疫苗及血清免疫球蛋白G对毒素A的抗体反应。
Infect Immun. 2003 Mar;71(3):1608-10. doi: 10.1128/IAI.71.3.1608-1610.2003.
2
Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.两组分艰难梭菌类毒素疫苗诱导的系统抗体应答可预防仓鼠艰难梭菌相关性疾病。
J Med Microbiol. 2013 Sep;62(Pt 9):1394-1404. doi: 10.1099/jmm.0.056796-0. Epub 2013 Mar 21.
3
Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.艰难梭菌感染重组毒素片段疫苗的研发
Vaccine. 2014 May 19;32(24):2812-8. doi: 10.1016/j.vaccine.2014.02.026. Epub 2014 Mar 21.
4
A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.一种靶向艰难梭菌毒素A受体结合域的DNA疫苗。
Vaccine. 2009 Jun 2;27(27):3598-604. doi: 10.1016/j.vaccine.2009.03.058. Epub 2009 Apr 9.
5
Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.艰难梭菌相关腹泻、炎症性肠病和囊性纤维化患者对艰难梭菌毒素 A 和 B 的循环抗体和记忆 B 细胞反应。
PLoS One. 2013 Sep 10;8(9):e74452. doi: 10.1371/journal.pone.0074452. eCollection 2013.
6
Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.通过皮下和黏膜免疫途径给仓鼠接种福尔马林灭活艰难梭菌疫苗的评估。
Infect Immun. 1995 Dec;63(12):4619-27. doi: 10.1128/iai.63.12.4619-4627.1995.
7
IgG antibody response to toxins A and B in patients with Clostridium difficile infection.艰难梭菌感染患者对毒素A和毒素B的IgG抗体反应。
Clin Vaccine Immunol. 2012 Sep;19(9):1552-4. doi: 10.1128/CVI.00210-12. Epub 2012 Jul 11.
8
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.艰难梭菌无症状携带与抗毒素A的IgG抗体血清水平
N Engl J Med. 2000 Feb 10;342(6):390-7. doi: 10.1056/NEJM200002103420604.
9
The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.重组乳球菌口服疫苗对艰难梭菌感染动物模型的保护作用。
BMC Gastroenterol. 2013 Jul 17;13:117. doi: 10.1186/1471-230X-13-117.
10
Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.表达艰难梭菌毒素A无毒结构域的鼠伤寒沙门氏菌aroA aroD疫苗的免疫原性
Infect Immun. 1999 May;67(5):2145-52. doi: 10.1128/IAI.67.5.2145-2152.1999.
引用本文的文献
1
De novo design of mini-protein binders broadly neutralizing Clostridioides difficile toxin B variants.广泛中和艰难梭菌毒素B变体的微型蛋白质结合剂的从头设计。
Nat Commun. 2024 Oct 2;15(1):8521. doi: 10.1038/s41467-024-52582-1.
2
Mucosal Vaccination Strategies against Infection.针对感染的黏膜疫苗接种策略
Vaccines (Basel). 2023 Apr 23;11(5):887. doi: 10.3390/vaccines11050887.
3
Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against .定植因子CD0873，一种有吸引力的抗……口服疫苗候选物
Microorganisms. 2021 Feb 2;9(2):306. doi: 10.3390/microorganisms9020306.
4
A Replicating Single-Cycle Adenovirus Vaccine Effective against .一种有效的复制型单周期腺病毒疫苗，可抵抗…… （原文未完整给出抵抗对象）
Vaccines (Basel). 2020 Aug 22;8(3):470. doi: 10.3390/vaccines8030470.
5
Immunogenicity and Protection from Receptor-Binding Domains of Toxins as Potential Vaccine Candidates for .毒素受体结合域的免疫原性及保护作用作为潜在疫苗候选物用于…… （原文结尾不完整）
Vaccines (Basel). 2019 Nov 8;7(4):180. doi: 10.3390/vaccines7040180.
6
Intravenous immunoglobulin therapy for refractory toxin colitis in chronic kidney disease: case reports and literature review.静脉注射免疫球蛋白治疗慢性肾脏病难治性毒素性结肠炎：病例报告及文献综述
NDT Plus. 2008 Feb;1(1):20-22. doi: 10.1093/ndtplus/sfm008. Epub 2007 Dec 19.
7
Development of a subunit vaccine for prevention of associated diseases: Biophysical characterization of toxoids A and B.开发用于预防相关疾病的亚单位疫苗：类毒素A和B的生物物理特性
Biochem Biophys Rep. 2017 Jan 5;9:193-202. doi: 10.1016/j.bbrep.2016.12.015. eCollection 2017 Mar.
8
Treatment of Recurrent Diarrhea.复发性腹泻的治疗
Gastroenterol Hepatol (N Y). 2006 Mar;2(3):203-208.
9
Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.开发一种含二元毒素的新型疫苗，用于预防艰难梭菌疾病，对NAP1菌株具有更高疗效。
PLoS One. 2017 Jan 26;12(1):e0170640. doi: 10.1371/journal.pone.0170640. eCollection 2017.
10
Clostridium difficile infection: Updates in management.艰难梭菌感染：管理方面的最新进展
Indian J Gastroenterol. 2017 Jan;36(1):3-10. doi: 10.1007/s12664-016-0719-z. Epub 2016 Dec 20.
本文引用的文献
1
Prospects for a vaccine for Clostridium difficile.艰难梭菌疫苗的前景。
BioDrugs. 1998 Sep;10(3):173-81. doi: 10.2165/00063030-199810030-00001.
2
Clinical practice. Antibiotic-associated diarrhea.临床实践。抗生素相关性腹泻。
N Engl J Med. 2002 Jan 31;346(5):334-9. doi: 10.1056/NEJMcp011603.
3
Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain.由一株耐克林霉素的A 型阴性肠毒素艰难梭菌引起的医院内艰难梭菌相关性腹泻暴发。
Eur J Clin Microbiol Infect Dis. 2001 Aug;20(8):528-34. doi: 10.1007/s100960100550.
4
Clostridium difficile.艰难梭菌
Gastroenterol Clin North Am. 2001 Sep;30(3):753-77, ix-x. doi: 10.1016/s0889-8553(05)70209-0.
5
Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay.与一种毒素A免疫测定法未检测到的艰难梭菌变异菌株相关的致死性假膜性结肠炎。
Ann Intern Med. 2001 Sep 18;135(6):434-8. doi: 10.7326/0003-4819-135-6-200109180-00012.
6
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.针对毒素A的抗体反应与预防艰难梭菌复发性腹泻之间的关联。
Lancet. 2001 Jan 20;357(9251):189-93. doi: 10.1016/S0140-6736(00)03592-3.
7
Role of antibody response in outcome of antibiotic-associated diarrhoea.
Lancet. 2001 Jan 20;357(9251):158-9. doi: 10.1016/S0140-6736(00)03582-0.
8
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.给予健康成年人递增剂量艰难梭菌类毒素疫苗的安全性和免疫原性。
Infect Immun. 2001 Feb;69(2):988-95. doi: 10.1128/IAI.69.2.988-995.2001.
9
Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease.一株引起人类临床疾病的艰难梭菌变异菌株的毒素基因分析。
Infect Immun. 2000 Oct;68(10):5480-7. doi: 10.1128/IAI.68.10.5480-5487.2000.
10
Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile.由艰难梭菌毒素A（-）B（+）菌株引起的伪膜性结肠炎。
J Clin Microbiol. 2000 Apr;38(4):1696-7. doi: 10.1128/JCM.38.4.1696-1697.2000.
Zotero 插件